Ansa Biotechnologies, Inc., announced that it has synthesized and delivered complex clonal DNA sequences to multiple customers participating in its Early Access Program.

uBriGene, a cell & gene therapy contract development and manufacturing organization, is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.

Scribe Therapeutics Inc. has announced a strategic collaboration with Prevail Therapeutics, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.

An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.

Agilent Technologies Inc. has announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types.